Similarly, treatment with Silybin, another PPARα agonist, effectively alleviates the symptom of NAFLD in the clinic by reducing fat mass and inducing CPT-1 and MCAD expression [37]. Interestingly, treatment with CLP also enhanced the expression of hepatic PPARα, CPT-1 and MCAD in the HFD-fed mice, which may contribute to its beneficial effect on NAFLD. The gene discussed is ACADM; the disease is metabolic dysfunction-associated steatotic liver disease.